We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -38.00 | -0.32% | 11,988.00 | 12,014.00 | 12,018.00 | 12,144.00 | 11,882.00 | 12,070.00 | 2,340,814 | 16:35:09 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.28 | 186.27B |
From Apr 2019 to Apr 2024
By Michael Dabaie
Clinical-stage immuno-oncology company Forty Seven Inc. (FTSV) said it will collaborate with AstraZeneca PLC's (AZN) Acerta Pharma.
Acerta will sponsor a clinical trial evaluating Forty Seven's CD47 antibody 5F9 in combination with rituximab plus Acerta's Calquence in patients with diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin's lymphoma.
The study aims to build on results already reported from a Phase 1b study of 5F9 in combination with rituximab in non-Hodgkin's lymphoma patients by including a third agent, acalabrutinib, the company said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 10, 2019 08:40 ET (12:40 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
